Effect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/ Kexin Type 9 Inhibitors

被引：5
|
作者：
Kazi, Dhruv S. [1 ]
Penko, Joanne [1 ]
Ollendorf, Daniel A. [2 ]
Coxson, Pamela G. [1 ]
Bibbins-Domingo, Kirsten [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Inst Clin & Econ Review, Boston, MA USA
来源：
ANNALS OF INTERNAL MEDICINE | 2018年 / 168卷 / 12期
关键词：
D O I：
10.7326/M17-3367
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：896 / +
页数：3
相关论文
共 50 条
  • [21] Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Real Practice
    Gayoso-Rey, Monica
    Diaz-Trastoy, Olaia
    Yaiza Romero-Ventosa, Elena
    Garcia-Beloso, Nerea
    Gonzalez-Freire, Lara
    Lorenzo-Lorenzo, Karina
    Mantinan-Gil, Beatriz
    Palmeiro-Carballeira, Regina
    Bravo-Amaro, Marisol
    del Mar Lopez-Gil-Otero, Maria
    Martinez-Reglero, Cristina
    Crespo-Diz, Carlos
    Fernandez-Catalina, Pablo
    Pineiro Corrales, Guadalupe
    CLINICAL THERAPEUTICS, 2021, 43 (04) : E111 - E121
  • [22] Proprotein convertase subtilisin/kexin type 9 and lipid metabolism
    Spolitu, Stefano
    Dai, Wen
    Zadroga, John A.
    Ozcan, Lale
    CURRENT OPINION IN LIPIDOLOGY, 2019, 30 (03) : 186 - 191
  • [23] Depressive Symptoms and Proprotein Convertase Subtilisin/Kexin Type 9
    Macchi, C.
    Buoli, M.
    Favero, C.
    Pesatori, A.
    Vigna, L.
    Corsini, A.
    Sirtori, C.
    Bollati, V.
    Ruscica, M.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2020, 22 (05): : S92 - S92
  • [24] Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: An unsolved mystery
    Liberopoulos, Evangelos
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2021, 28 (08) : 813 - 815
  • [25] Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis
    Ferraz-Amaro, I.
    Lopez-Mejias, R.
    Ubilla, B.
    Genre, F.
    Tejera-Segura, B.
    de Vera-Gonzalez, A. M.
    Gonzalez-Rivero, A. F.
    Olmos, J. M.
    Hernandez, J. L.
    Llorca, J.
    Gonzalez-Gay, M. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (06) : 1013 - 1019
  • [26] Proprotein convertase subtilisin/kexin type 9 in kidney disease
    Schmit, David
    Fliser, Danilo
    Speer, Thimoteus
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 (08) : 1266 - 1271
  • [27] Advancing Research on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Scientometric Analysis
    Matin, Abdul
    Chaudhry, Gul-e-Saba
    Azra, Mohamad Nor
    Gazli, Mohamad
    Sung, Yeong Yik
    Muhammad, Tengku Sifzizul TENGku
    MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2024, 31 (04): : 14 - 34
  • [28] PERSISTENCE AND ADHERENCE WITH PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITORS IN CLINICAL PRACTICE
    Hines, Dionne
    Rane, Pallavi
    Patel, Jeetvan
    Harrison, David
    Wade, Rolin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 159 - 159
  • [29] Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons
    Bajaj, Navkaranbir S.
    Patel, Nirav
    Kalra, Rajat
    Ahmad, Amier
    Venkatraman, Anand
    Arora, Garima
    Arora, Pankaj
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2018, 4 (02) : 132 - 141
  • [30] Statins plus ezetimibe in the era of proprotein convertase subtilisin/kexin type 9 inhibitors
    De Luca, Leonardo
    Corsini, Alberto
    Uguccioni, Massimo
    Colivicchi, Furio
    KARDIOLOGIA POLSKA, 2020, 78 (09) : 850 - 860
12345